SCYNEXIS, Inc. - SCYX STOCK NEWS

SCYNEXIS, a biotechnology firm, reported Q1 2022 financial results, with net revenues of $0.7 million from BREXAFEMME® (ibrexafungerp), launched in September 2021. The drug achieved nearly 4,000 prescriptions in the quarter and is covered by insurance plans representing 55% of commercially insured lives. The company initiated a global Phase 3 study (MARIO) for ibrexafungerp and reported positive interim results from trials, showing an 83.2% clinical response rate in patients. As of March 31, 2022, SCYNEXIS had $95.2 million in cash, projected to last into Q1 2024.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced positive interim results from the ongoing Phase 3 FURI study, showing that 71.4% of patients with refractory vulvovaginal candidiasis (VVC) treated with ibrexafungerp achieved successful clinical outcomes. Ibrexafungerp is effective for patients intolerant to standard antifungal therapies. The treatment was generally safe and well-tolerated. The company plans to submit a supplemental New Drug Application to the FDA based on positive findings from another study, furthering the potential for label expansion by year-end 2022.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced a conference call and webcast scheduled for May 12, 2022, at 8:30 a.m. ET, to discuss its first-quarter financial results for the period ended March 31, 2022. The live audio webcast will be accessible via SCYNEXIS's Investor Relations page, and a replay will be available for 90 days post-event. SCYNEXIS focuses on developing innovative antifungal therapies, with its lead product, ibrexafungerp, recently approved by the FDA and set for commercial launch in the U.S. under the brand name BREXAFEMME.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced a product theater presentation scheduled for May 7, 2022, at the ACOG Annual Meeting in San Diego. The focus will be on clinical data from the ongoing FURI study of ibrexafungerp, the first new antifungal class approved in over 25 years. The presentation will include outcomes from an open-label study addressing refractory vulvovaginal candidiasis. Ibrexafungerp shows promise as a broad-spectrum systemic antifungal, with FDA approvals and orphan drug designations supporting its innovative approach to treating drug-resistant infections.

SCYNEXIS announced positive interim results from its Phase 3 CARES study, showing a complete or partial response in 78% of 18 patients treated with ibrexafungerp for Candida auris infections, a significant pathogen linked to recent outbreaks. The data is consistent with previous studies for invasive candidiasis and candidemia. Additionally, new in vivo research supports ibrexafungerp's potential for treating mucormycosis, particularly during the COVID-19 pandemic. These findings underscore the urgent need for new therapies for drug-resistant infections.

SCYNEXIS, Inc. (Nasdaq: SCYX) has successfully closed a public offering, raising $45.0 million. The offering included 3,333,333 shares of common stock, along with pre-funded and traditional warrants. Shares were priced at $3.00 each, while pre-funded warrants were priced at $2.999. Additionally, the underwriters have a 30-day option to purchase up to 2,250,000 additional shares. The funds will support the company's continued development of its lead antifungal asset, ibrexafungerp, as they pursue market opportunities.

SCYNEXIS, Inc. (Nasdaq: SCYX) announced a public offering of common stock, pre-funded warrants, and warrants priced at $3.00 per share and $2.999 per pre-funded warrant, aiming for gross proceeds of approximately $45 million. The offering includes 3,333,333 shares of common stock, 11,666,667 pre-funded warrants, and 15,000,000 warrants, with a seven-year term and an exercise price of $3.45 per share. An option exists for underwriters to purchase an additional 2,250,000 shares. This offering is subject to market conditions and closing requirements.

SCYNEXIS announced interim data from its Phase 3 FURI and CARES studies showing positive results for oral ibrexafungerp in treating refractory fungal infections. The studies involve over 130 patients, indicating a 61.1% rate of clinical improvement across both trials. Ibrexafungerp addresses severe infections caused by drug-resistant Candida species, with a notable 88.9% response rate in the CARES study. Results will be shared at the ECCMID in April 2022, reinforcing SCYNEXIS's initiative to build a robust antifungal franchise.

SCYNEXIS, Inc. (NASDAQ: SCYX) has initiated an underwritten public offering of common stock and warrants, including pre-funded warrants. The underwriters may purchase up to an additional 15% of the offered shares within 30 days. This offering is subject to market conditions, and no guarantees are made regarding its completion or terms. Guggenheim Securities is the book-running manager. The offering is based on a shelf registration statement filed with the SEC, originally effective in January 2021. SCYNEXIS is known for its lead antifungal drug, ibrexafungerp, aimed at treating drug-resistant infections.